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Background. Repeated mass drug administration (MDA) with preventive chemotherapies is the mainstay of morbidity control
for schistosomiasis and soil-transmitted helminths, yet the World Health Organization recently reported that less than one-third of
individuals who required preventive chemotherapies received treatment.
Methods. Coverage of community-directed treatment with praziquantel (PZQ) and albendazole (ALB) was analyzed in 17 vil-
lages of Mayuge District, Uganda. National drug registers, household questionnaires, and parasitological surveys were collected to
track 935 individuals before and after MDA. Multilevel logistic regressions, including household and village effects, were speciﬁed
with a comprehensive set of socioeconomic and parasitological variables. The factors predicting who did not receive PZQ and ALB
from community medicine distributors were identiﬁed.
Results. Drug receipt was correlated among members within a household, and nonrecipients of PZQ or ALB were proﬁled by house-
hold-level socioeconomic factors. Individualswere less likely to receive either PZQorALB if theyhad aMuslimhousehold head or lowhome
quality, belonged to the minority tribe, or had settled for more years in their village. Untreated individuals were also more likely to belong
to households that did not purify drinking water, had no home latrine, and had no members who were part of the village government.
Conclusions. Theﬁndings demonstrate how to locate and target individualswho are not treated inMDA. Infection risk factorswere not
informative. In particular, age, gender, and occupation were unable to identify non-recipients, althoughWorld Health Organization guide-
lines rely on these factors. Individuals of low socioeconomic status, minority religions, and minority tribes can be targeted to expandMDA
coverage.
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An estimated 207 and 576 million individuals, respectively, are
infected with Schistosoma and hookworm species [1, 2]. The
majority of schistosomiasis infections occur in childhood and,
if left untreated, can cause irreversible disease in adulthood [1].
These diseases include portal hypertension (caused by Schisto-
soma mansoni or Schistosoma japonicum) and bladder squa-
mous cell carcinoma (caused by Schistosoma haematobium).
Heavy hookworm infection intensity, which can be found in
children but is most common in adults, can lead to iron deﬁ-
ciency anemia, protein malnutrition, and diarrhea [2].
Mass drug administration (MDA) is the mainstay of morbid-
ity control for human helminthiases [3].MDA is the delivery, en
masse, of free single-treatment preventive chemotherapies
(PCs) in regular intervals to endemic populations. PCs are “pre-
ventive’” in that they successfully curtail morbidity and are safe
to administer to uninfected individuals. Endemic areas are clas-
siﬁed by rapid sampling, usually of children in primary schools,
to assess infection prevalence. Schistosomiasis is treated with
praziquantel (PZQ), and soil-transmitted helminths (STHs)
are treated with albendazole (ALB) or mebendazole. Repeated
annual or biannual treatments are necessary mainly because
of susceptibility to reinfection after treatment [4, 5]. Coverage
(the proportion of persons requiring and receiving PCs through
MDA) was an estimated 16.88% among all individuals requiring
treatment for schistosomiasis in 2012 [6] and 30.63% among
children needing PCs for STHs in 2011 [7].
In this article, we identify the factors that affect access to PCs
during MDA. We focus on community-directed treatment
(CDT), the only mode of MDA delivery of PZQ and ALB to
both adults and children [8–10]. CDT involves 2 locally selected
community medicine distributors (CMDs), who are trained an-
nually by a district health ofﬁcer (DHO) to administer correct
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treatment dosages, determine ineligibility of individuals, and re-
cord these treatments in national drug registers [3]. Apart from
receiving remuneration for training, CMDs are unpaid
volunteers.
A nonrecipient is someone who was not approached by the
CMD or was offered treatment and deliberately refused (non-
compliance) [11]. Individuals who are not approached by
CMDs often include hard-to-reach or mobile populations,
whereas noncompliance has been associated with a fear of ad-
verse effects, social differences between the recipient and CMD,
and a lack of health education [11, 12]. In sub-Saharan Africa,
rates of compliance with ivermectin (IVM) CDT for onchocer-
ciasis and lymphatic ﬁlariasis was higher among men, certain
ethnic groups, Christians, and landowners [13–17]. For schisto-
somiasis infections in Uganda, qualitative analyses [11, 18] sug-
gested that at-risk ﬁshermen and adults did not receive PZQ
treatment. These proﬁles of CDT nonrecipients have been poor-
ly and incompletely described. Analyses of PZQ receipt [11, 18]
relied on qualitative accounts of special interest groups, and
studies of IVM distribution assessed only noncompliance
[13–17].
This article presents what is to our knowledge the ﬁrst quan-
titative assessment of nonrecipients of CDT for schistosomiasis
and STHs. Research was conducted in Uganda, the ﬁrst country
in sub-Saharan Africa to adopt MDA for schistosomiasis in
2003 and to integrate control measures with STHs in 2004
[19, 20]. National drug registers, household questionnaires,
and parasitological surveys were collected to determine the ob-
servable factors that identify and predict which individuals do
not receive PZQ or ALB treatment from CMDs.
METHODS
Study Location and Participant Selection
This study was conducted from August-November 2013 in the
context of a routine national helminth control program. Seven-
teen villages were surveyed within 5 kilometers of Lake Victoria
in Mayuge District, Uganda (see Supplementary Text for village
selection). This area is endemic only for intestinal schistosomia-
sis (S. mansoni), and the species of hookworm is unknown. In
these villages, 517 households and 1034 participants were se-
lected by CMDs, and ≥30 households within each village
were sampled. Researchers provided CMDs with stratiﬁed sam-
pling instructions to sample 1 adult and 1 child from each home
(see Supplementary Text for additional details). Paired sam-
pling was used to determine whether CMDs distributed treat-
ments from home to home as trained.
Data Sources
Figure 1 presents the chronologyof data collected before and after
MDA for the 1034 study participants. In August–September
2013, data were ﬁrst collected to measure the baseline (pretreat-
ment) infection intensities of the study participants. CMDs
recruited participants without the presence of researchers,
which ensured that participants were identiﬁable and not
hard for CMDs to reach. Each participant provided 1 stool sam-
ple, and standard thick-smear (41.7 mg) Kato-Katz methods
[21] were used to count hookworm eggs (within 30 minutes
of preparation) and S. mansoni eggs (24 hours after prepara-
tion) for 2 slides. At this time, CMDs were not informed of
forthcoming MDA or research activities.
During the second period of this study, MDA was ongoing.
In the last 2 weeks of September, the DHO trained CMDs and
provided PZQ, ALB, IVM, and new national drug registers. The
DHO instructed CMDs to deliver PZQ in the ﬁrst week of Oc-
tober, followed by a package of ALB and IVM (for lymphatic
ﬁlariasis) in the second week. The DHO was able to conﬁrm
that all CMDs completed their training, received enough pills
to treat all eligible persons in their village, and knew of all the
homes in their village. To avoid national and district adminis-
trative inefﬁciencies, the DHO was provided with a car to enable
the timely completion of CMD training. All CMDs were trained
and ready to begin MDA by 1 October 2013. No instruction was
given to CMDs by the DHO to treat the study participants, and
researchers were not present during any MDA activities.
Figure 1. Chronology of data collected and schematic of analysis completed. Data
were collected over 4 time periods for the initial 1034 participants who provided
stool samples for baseline parasitology. The source of the initial sampling or retriev-
al of these participants was the village community medicine distributor or an inde-
pendent team of surveyors. Not all data sources were available for the initial 1034
participants. Refer to “Methods” section for a full explanation.
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After MDA, follow-up parasitology and household question-
naires were conducted. Villages were visited beginning 1 No-
vember 2013. CMDs were told that the purpose of these
surprise visits was to examine drug efﬁcacy from the follow-
up parasitology, and laboratory technicians would need to
know which participants received PZQ or ALB. A list of the ini-
tial 1034 participants was provided to CMDs, who were able to
retrieve 860 of these individuals to provide a second stool sam-
ple. A researcher also inspected the national registers with the
CMDs and recorded which of the initial 1034 participants
received PZQ, ALB, or IVM. CMDs were involved only in
research activities that reﬂect routine practices in MDA. Ac-
cordingly, after the second round of parasitology, independent
teams of local villagers were used to conduct household surveys
in their respective villages. These surveys gathered socioeco-
nomic information on 935 of the 1034 initial participants
(group A in Figure 1). Among these 935 individuals, 779
were included in the group of 860 individuals who provided a
follow-up stool sample (group B in Figure 1). No differences in
baseline infection intensity, age, or sex were found between in-
dividuals included in the household survey and those who were
not interviewed (Supplementary Table 1).
Variables
Infection intensity was calculated as eggs per gram. Egg counts for
each slide (41.7 mg) were multiplied by 24 and averaged to deter-
mine eggs per gram. Individuals with ≥1 detectable egg per gram
were classiﬁed as infected. Baseline village prevalence was calculat-
ed as the proportion of infected individuals from the initial 1034
participants. PZQ, ALB, and IVM treatments are represented as
binary variables; these indicators are positive if the CMD recorded
an individual as receiving the drug in the national register. Socio-
economic variables were included from the household survey to
capture social status, wealth, demographics, and other observable
characteristics of individuals (see Supplementary Text for full var-
iable deﬁnitions). Table 1 presents a summary of all variables.
Statistical Analysis
The data were analyzed with Stata software, version 13.1 (Stata-
Corp). To identify who did not receive PZQ or ALB, the 935
individuals from group A in Figure 1 were examined. Three-
level, hierarchical logistic regressions were used [22]. Indivi-
duals were nested in 510 households, located in 17 villages.
Socioeconomic factors and the total homes in each village
were predictors of PZQ and ALB receipt. Baseline individual in-
fection intensity and baseline village infection prevalence of S.
mansoni and hookworm were covariates, respectively, for PZQ
and ALB. Because IVM is coadministered with ALB, this vari-
able was examined in the ALB model but dropped due to col-
linearity. There was insufﬁcient evidence that the error terms of
the PZQ and ALB models were correlated (χ2 = 3.20; P = .07), so
separate regressions were used.
Intraclass correlation (ICC) coefﬁcients are reported to de-
scribe the correlation of drug receipt within a household [23].
The crude global R2 was calculated as the square of the correla-
tion between predicted and actual values of drug receipt [24].The
proportional reduction of error variance explained by the full
model (conditional R2) was calculated as explained by Nakagawa
and Schielzeth [25]. Furthermore, the area under the receiver op-
erating characteristic curve was reported [22] and corrected for
overﬁtting with 10- and 5-fold cross-validation [26]. An auxiliary
analysis of treatment impact on infection prevalence is provided
in Supplementary Text and Supplementary Tables 2–5.
Ethics
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RESULTS
Proportion of Individuals Receiving Treatment
For individuals from group A in Figure 1, which was used in the
drug receipt model, 37.86% (354 of 935) received both PZQ and
ALB, 14.76% (138 of 935) received PZQ without ALB, and
3.21% (30 of 935) received ALB without PZQ. Therefore, a
large proportion of study participants (44.17%, 413/935) re-
ceived neither PZQ nor ALB. Table 1 presents the personal
characteristics of untreated and treated individuals.
Reasons for Not Receiving Treatment
Coverage reported by CMDs in the drug registers did not differ
signiﬁcantly for PZQ and was approximately 10% lower for
ALB than the coverage measured from household surveys (Sup-
plementary Table 6). Household heads explained why individ-
uals in their home did not receive any drugs (including IVM).
Reasons were available for 86.29% (302 of 350) of these individ-
uals (group A, Figure 1). No drug availability was the most com-
mon response for being untreated (70.53%; 213 of 302).
Additional explanations included a lack of health education
(12.25%; 37 of 302), ineligibility (11.26%; 34 of 302), and non-
compliance (6.0%; 18 of 302) (see Supplementary Text for de-
tailed deﬁnitions of these reasons).
Factors Describing Nonrecipients of PZQ
Figure 2 presents the factors predicting PZQ treatment; the full
model is presented in Supplementary Table 7. PZQ receipt was
correlated between children and adults in the same household.
Individuals within the same household were 76.35% more likely
to have the same drug receipt status than individuals of different
households in their village (ICC; Supplementary Table S7). For
individual characteristics, only heavy S. mansoni infection in-
tensity was associated with a decreased probability of PZQ treat-
ment (P = .01).
Four household-level socioeconomic factors inﬂuenced PZQ
distribution. Belonging to a household with a Muslim head was
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associated with a 51.63% lower likelihood of receiving PZQ than
belonging to a household with a Christian head (this was bor-
derline signiﬁcant; P = .054). Muslims were the minority reli-
gion in the study area (Table 1). Compared with Christians,
however, Muslims were neither less educated (mean educational
level, 3.70 for Muslims and 3.36 for Christians; P = .12) nor
more noncompliant (2.18% (6/275) of Muslims were noncompli-
ant vs 2.00% (13/660) of Christians; P = .83). Moreover, there
were Muslim CMDs (9 of 34) in the predominantly Muslim
villages. Kinship was another social factor affecting PZQ
distribution. Households in the village majority tribe were 2.11
times more likely to receive PZQ than households in minority
tribes (P = .02). For household wealth, each point increase in
home quality score (eg, improvement in wall materials from
mud to aluminum or from aluminum to brick) increased the
probability that the CMD would provide PZQ to an individual
by 17.97% (P = .002). Households that puriﬁed drinking water
were 2.12 times more likely to receive PZQ than households
that did not treat, ﬁlter, or boil water collected from streams or
lakes P = .04.












Baseline EPG, mean (SD)b
Schistosoma mansoni 219.7 (870.4) 149.8 (598.8) 297.3 (1091.4) 158.6 (610.9) 262.3 (1011.1)
Hookworm 348.6 (1486.2) 254.1 (1107.7) 453.6 (1812.0) 262.5 (1110.5) 408.5 (1698.0)
Age, mean (SD) 24.2 (16.5) 24.5 (16.5) 23.8 (16.5) 24.8 (16.4) 23.7 (16.7)
Female, No. (%) 564 (60.3) 286 (58.1) 278 (62.8) 232 (60.4) 332 (60.3)
Educational level, mean (SD)c 3.5 (3.0) 3.5 (3.1) 3.5 (2.9) 3.4 (3.1) 3.5 (2.9)
Occupation, No. (%)d
No income-earning occupation 607 (64.9) 316 (64.2) 291 (65.7) 242 (63.0) 365 (66.2)
Fisherman or fishmonger 41 (4.4) 21 (4.3) 20 (4.5) 17 (4.4) 24 (4.4)
Business owner 25 (2.7) 10 (2.0) 15 (3.4) 12 (3.1) 13 (2.4)
Rice farmer 36 (3.9) 8 (1.6) 28 (6.3) 9 (2.3) 27 (4.9)
Other farmer 173 (18.5) 102 (20.7) 71 (16.0) 75 (19.5) 98 (17.8)
Schoolteacher 10 (1.1) 5 (1.0) 5 (1.1) 4 (1.0) 6 (1.1)
Health worker 6 (0.6) 6 (1.2) 0 (0) 5 (1.3) 1 (0.2)
Other 37 (4.0) 24 (4.9) 13 (2.9) 20 (5.2) 17 (3.1)
Muslim household head, No. (%) 275 (29.4) 121 (24.6) 154 (34.8) 97 (25.3) 178 (32.3)
Household head belongs to village majority
tribe, No. (%)
500 (53.5) 294 (59.8) 206 (46.5) 219 (57.0) 281 (51.0)
Time household settled in village,
mean (SD), y
16.7 (11.5) 17.4 (11.3) 16.0 (11.7) 16.2 (11.0) 17.1 (11.9)
Home quality score, mean (SD)e 7.4 (3.3) 7.9 (3.2) 6.7 (3.3) 7.9 (3.3) 7.0 (3.2)
Households, No. (%)
With purified drinking water 400 (42.8) 221 (44.9) 179 (40.4) 177 (46.1) 223 (40.5)
With no home latrine 60 (6.4) 23 (4.7) 37 (8.4) 15 (3.9) 45 (8.2)
Including former or current village
chairman
44 (4.7) 29 (5.9) 15 (3.4) 25 (6.5) 19 (3.4)
Including other former or current village
government member
81 (8.7) 52 (10.6) 29 (6.5) 39 (10.2) 42 (7.6)
Seeking medical care from private clinics 524 (56.0) 278 (56.5) 246 (55.5) 226 (58.9) 298 (54.1)
Baseline prevalence, No. (%)f
S. mansoni 397 (42.5) 195 (39.6) 202 (45.6) 165 (43.0) 232 (42.1)
Hookworm 372 (39.8) 175 (35.6) 197 (44.5) 130 (33.9) 242 (43.9)
Abbreviations: ALB, albendazole; EPG, eggs per gram. PZQ, praziquantel; SD, standard deviation.
a The number of homes in the 17 study villages ranged from 68 to 411 households with a mean (SD) of 215.12 (89.88) homes. Study participants had lived in their village a mean of 16.74 years,
and approximately 47% did not belong to the majority tribe (Mudama or Musoga). Homes were most often made of mud walls and thatched roofs. Only 29.41% of the sample wasMuslim; the
rest identified as Christian.
b Baseline EPG is the infection status before treatment distribution.
c Educational level, the highest level attained, was an ordinal variable from 0–16. The levels were no education 0, primary 1–7, senior 1–6 (levels 8–13), diploma (level 14), some university (level
15), and completed university (level 16).
d Occupation represents income-earning work for each individual. The reference category is no income-earning occupation, which included adults and children who did not work, as well as
housewives.
e Home quality score is a count variable in which the roof, wall, and floor materials were ranked in quality from 1 to 4 and summed. Scores ≤3 indicated the worst possible home quality, which
was the case for 24.92% of the sample (233 of 935 individuals). Among treated individuals only 18.09% of PZQ recipients (89 of 492) and 19.27% of ALB recipients (74 of 384) had the worst
quality homes, compared with 32.51% (144 of 443) and 28.86% (159 of 551) for PZQ and ALB nonrecipients, respectively.
f Of the S. mansoni and hookworm infections, 12.78% were coinfections.
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Factors Describing Nonrecipients of ALB
Figure 3 presents the determinants of ALB receipt; the full
model is provided in Supplementary Table 8. ALB receipt was
correlated between individuals within the same household.
Children and their caretakers were 91.74% more likely to have
the same ALB receipt status than individuals of different house-
holds in their village (ICC; Supplementary Table 8).
Individual-level variables were insigniﬁcant (P > .05) for ALB
distribution. However, household-level socioeconomic factors
were relevant for ALB receipt. Individuals in homes with Muslim
household heads were 78.45% less likely to receive ALB than those
in Christian households (P = .007). For each point increase in
home quality score, the probability of ALB treatment increased
by 25.40% (P = .003). In Uganda, the chairman has the highest
formal position in the village government. Compared with house-
holds with no village governmentmembers, ALB receipt was 16.68
times more likely when the household included a former or cur-
rent chairman (P = .002). Similarly, any current or former village
government member in the household (not including chairmen)
was associated with a 10.21-fold increase (P = .02) in the likeli-
hood of ALB treatment. For each additional year that the house-
hold had been settled in their village, individuals within that home
were 5% less likely to receive ALB (P = .03). The lack of access to a
shared or private home latrine, which excludes public latrines, was
related to a 94.80% lower likelihood of ALB receipt (P = .002).
Onevillage-level factoraffectedALBdistribution. Individuals be-
longing to villages with high hookworm infection prevalence were
9.15% less likely to receive ALB than those in villages with low
hookworm infection prevalence (P < .001). Determinants of ALB
receipt remained robust when health workers were removed from
the analysis (Supplementary Table 9). Moreover, all results for
PZQ and ALB receipt remained when baseline S. mansoni and
hookworm infection intensities were removed from the multilevel
regressions (SupplementaryTables 10 and 11). For reference, unad-
justed univariate regressions are shown in Supplementary Table 12.
DISCUSSION
World Health Organization bulletins from 2013 and 2014 indi-
cate that more than 200 and 600 million persons who require,
Figure 2. Determinants of praziquantel (PZQ) treatment receipt. The odds ratios are shown from the full multilevel model presented in Supplementary Table 7. The reference
line at 1 indicates no increase or decrease in the likelihood of PZQ receipt. The 95% confidence intervals (CIs) also are plotted, and significant odds ratios are presented with
solid lines. Occupation represents income-earning work for each individual; the reference category is no income-earning occupation, which included adults and children who did
not work, as well as housewives. *P < .05; †P = .054. Abbreviations: EPG, eggs per gram; LN, natural log.
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respectively, PZQ for S. mansoni infections and ALB or meben-
dazole for hookworm infections do not receive treatment
through MDA [6, 7]. We proﬁled untreated individuals in May-
uge District, Uganda, during the context of routine, communi-
ty-based MDA. More than 44% of 935 individuals in 17 villages
did not receive PZQ or ALB.
Existing World Health Organization guidelines prioritize in-
dividuals for treatment based on age, sex, and high-risk occupa-
tions for S. mansoni or hookworm infections [3], but these
infection risk factors were unable to identify nonrecipients of
MDA. Two household-level factors proﬁled untreated individ-
uals: socioeconomic status and minority group afﬁliation. Schis-
tosomiasis and hookworm infections are prevalent among the
rural poor, who lack access to safe water and sanitation. We
found that within such impoverished communities, socioeco-
nomic divisions persist and determine who receives treatment
for intestinal helminths. Individuals of low economic standing,
who belonged to households with poor home quality, no access
to puriﬁed water, and no home latrine, were less likely to receive
PZQ or ALB. Similarly, low social status was negatively associ-
ated with treatment receipt. Households without members in
the current or former village government were >10 times less
likely to be treated. Belonging to a minority religion or tribe
was also negatively associated with drug receipt.
Targeting observable socioeconomic factors could not only
expand treatment coverage but also affect the prevalence of in-
fection and address treatment fatigue. Nonrecipients had either
heavy S. mansoni infection intensities or belonged to villages
with a high prevalence of hookworm infection. Long-term res-
idents were also 5% less likely to receive ALB, though this was a
small effect. These individuals might experience treatment fa-
tigue because of previous participation in MDA, which has
been ongoing in the study area for 10 years [27]. To externally
validate these proﬁles of untreated individuals, future studies
are required in other countries implementing MDA.
Enough pills to treat all villagers were provided to CMDs and
available in the village. However, 70% of untreated individuals
believed drugs were not available because they had not been
Figure 3. Determinants of albendazole (ALB) receipt. The odds ratios are shown from the full multilevel model presented in Supplementary Table 8. The reference line at 1
indicates no increase or decrease in the likelihood of ALB receipt. The 95% confidence intervals (CIs) are also plotted, and significant odds ratios are presented with solid lines.
Occupation represents income-earning work for each individual; the reference category is no income-earning occupation, which included adults and children who did not work,
as well as housewives. *P < .05. Abbreviations: EPG, eggs per gram; LN, natural log.
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approached by CMDs and had not heard of the drug availability
from other villagers. These untreated individuals indicated that
they would comply if offered treatment by CMDs. Fleming et al
[28] show in our study region that CMDs request remuneration
for the time required to treat all households, but this does not
explain why households of low socioeconomic status were dis-
proportionately left untreated. Assuming that households of low
socioeconomic status were hard to reach seems unlikely, be-
cause all individuals were found and contacted by CMDs in a
baseline parasitology task before MDA (see Data Sources in
the “Methods” section). To assess why households of lower so-
cioeconomic status were not treated, research is needed on vil-
lage social interactions [29]. Potential issues to explore include
the inﬂuence of high social status households on CMDs, the
similarity of treated households to CMDs, and the frequency
of social interactions between CMDs and untreated households.
The analysis of coverage from MDA drug registers has been
shown to be problematic owing to overreporting [30]. However,
no signiﬁcant differences were found between reported coverage
from the drug registers and self-reported coverage from household
surveys (Supplementary Table 6). This may be due to the sampling
procedure used in this study, whereby study participants were se-
lected in a task that was unrelated to MDA monitoring and was
undertaken before the training and delivery of drugs to CMDs.
The CMDs were unaware of future monitoring, surprise visits oc-
curred, and no payments were provided for distribution. This
method cannot increase the number of individuals who are re-
corded in drug registers by CMDs [11]. However, selecting indi-
viduals before administering and recording treatments may ensure
the validity of CMD-reported coverage and facilitate monitoring of
individuals who are not included in the national drug registers.
This study demonstrated how routinely collected drug regis-
ters can be used to obtain proﬁles of MDA nonrecipients. In
Mayuge District, an area that has received repeated MDA treat-
ments for S. mansoni and hookworm infections [27], coverage
was dependent on household socioeconomic factors. Infection
risk factors were not relevant for identifying untreated individ-
uals during community-based distribution when compared
with social characteristics, even though the study area had S.
mansoni and hookworm infection prevalence of greater than
50% [31, 32]. Household socioeconomic factors identiﬁed the
individuals failing to beneﬁt from PZQ and ALB treatments
and can be targeted to expand MDA coverage.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
Notes
Acknowledgments. We are thankful for critiques of this manuscript
from Drs Michelle Clements and Fiona Fleming as well as the very help-
ful comments from 4 anonymous reviewers. We appreciate the active
involvement and patience of the people of our 17 study villages in Mayuge
District, Uganda. The hard work of the laboratory technicians from the Vec-
tor Control Division in Uganda who collected the parasitology, the ﬁeld as-
sistants, and local village surveyors who collected household survey data
made this project possible. The Schistosomiasis Control Initiative (SCI) at
Imperial College London and the Schistosomiasis Research Group at the
University of Cambridge were instrumental to setting up this project and
providing insightful discussion during the formative stages of the study.
Financial support. This work was supported by the Vice Chancellor’s
Fund of the University of Cambridge, the SCI, the Wellcome Trust (pro-
gram grant 083931/Z/07/Z to D. W. D.), and The Netherlands Organization
for Scientiﬁc Research (grant 452-04-333 to E. B.).
Potential conﬂicts of interest. A. F. is the executive director of the
SCI. N. B. K. is employed by SCI. E. M. T. is the assistant commissioner
of health services for the Vector Control Division of Ministry of Health
and the national coordinator for SCI of the Neglected Tropical Diseases
Control/Elimination Programme in Uganda. All other authors report no po-
tential conﬂicts. All authors have submitted the ICMJE Form for Disclosure
of Potential Conﬂicts of Interest. Conﬂicts that the editors consider relevant
to the content of the manuscript have been disclosed.
References
1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water
resources development: systematic review, meta-analysis, and estimates of people
at risk. Lancet Infect Dis 2006; 6:411–25.
2. Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: as-
cariasis, trichuriasis, and hookworm. Lancet 2006; 367:1521–32.
3. World Health Organization. Preventive chemotherapy in human helminthiases,
coordinated use of anthelminthic drugs in control interventions: a manual for
health professionals and programme managers. 2006. Available at: http://
whqlibdoc.who.int/publications/2006/9241547103_eng.pdf. Accessed 1 October
2015.
4. Pinot de Moira A, Fulford A, Kabatereine N, Ouma J, BoothM, Dunne D. Analysis
of complex patterns of human exposure and immunity to Schistosomiasis manso-
ni: the inﬂuence of age, sex, ethnicity and IgE. PLoS Negl Trop Dis 2010; 4:e820.
5. Albonico M, Smith P, Ercole E, et al. Rate of reinfection with intestinal nematodes
after treatment of children with mebendazole or albendazole in a highly endemic
area. Trans R Soc Trop Med Hyg 1995; 89:538–41.
6. World Health Organization. Schistosomiasis: number of people receiving preven-
tive chemotherapy in 2012. Wkly Epidemiol Rec 2014; 89:21–8.
7. World Health Organization. Soil-transmitted helminthiases: number of children
treated in 2011. Wkly Epidemiol Rec 2013; 88:145–52.
8. Ivan E, Crowther NJ, Mutimura E, et al. Effect of deworming on disease
progression markers in HIV-1, infected pregnant women on antiretroviral thera-
py: a longitudinal observational study from Rwanda. Clin Infect Dis 2015;
60:135–42.
9. TurnerHC,WalkerM,Churcher TS, et al. Reaching the London declaration onneg-
lected tropical diseases goals for onchocerciasis: an economic evaluation of in-
creasing the frequency of ivermectin treatment in Africa. Clin Infect Dis 2014;
59:923–32.
10. Knopp S, Mohammed KA, Speich B, et al. Albendazole and mebendazole admin-
istered alone or in combination with ivermectin against Trichuris trichiura: a ran-
domized controlled trial. Clin Infect Dis 2010; 51:1420–8.
11. Parker M, Allen T. Does mass drug administration for the integrated treatment of
neglected tropical diseases really work? assessing evidence for the control of schis-
tosomiasis and soil-transmitted helminths in Uganda. Health Res Policy Syst
2011; 9:3.
12. Babu B, Kar S. Coverage, compliance and some operational issues of mass drug
administration during the programme to eliminate lymphatic ﬁlariasis in Orissa,
India. Trop Med Int Health 2004; 9:702–9.
13. Brieger W, Okeibunor J, Abiose A, et al. Characteristics of persons who complied
with and failed to comply with annual ivermectin treatment. Trop Med Int Health
2012; 17:920–30.
14. Brieger W, Otusanya S, Oke G, Oshiname F, Adeniyi J. Factors associated with
coverage in community-directed treatment with ivermectin for onchocerciasis
control in Oyo State, Nigeria. Trop Med Int Health 2002; 7:11–8.
15. Talbot J, Viall A, Direny A, et al. Predictors of compliance in mass drug admin-
istration for the treatment and prevention of lymphatic ﬁlariasis in Leogane, Haiti.
Am J Trop Med Hyg 2008; 78:283–8.
16. Njomo D, Mukoko D, Nyamongo N, Karanja J. Increasing coverage in mass drug
administration for lymphatic ﬁlariasis elimination in an urban setting: a study of
Malindi Town, Kenya. PLoS One 2014; 9:e83413.
206 • CID 2016:62 (15 January) • Chami et al
17. Njomo D, Amuyunzu-Nyamongo M, Mukoko D, Magambo J, Njenga S. Socioe-
conomic factors associated with compliance with mass drug administration for
lymphatic ﬁlariasis elimination in Kenya: descriptive study results. Ann Trop
Med PH 2012; 5:103–10.
18. Parker M, Allen T, Pearson G, Peach N, Flynn R, Rees N. Border parasites: schis-
tosomiasis control among Uganda’s ﬁsherfolk. J East Afr Stud 2012; 6:98–123.
19. Kabatereine N, Tukahebwa E, Kazibwe F, et al. Progress towards countrywide con-
trol of schistosomiasis and soil-transmitted helminthiasis in Uganda. Trans R Soc
Trop Med Hyg 2006; 100:208–15.
20. Fenwick A, Webster JP, Bosque-Oliva E, et al. The Schistosomiasis Control Initia-
tive (SCI): rationale, development and implementation from 2002–2008. Parasitol-
ogy 2009; 136:1719–30.
21. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear
technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972;
14:397–400.
22. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using Stata.
College Station, TX: Stata Press, 2008.
23. McGraw KO, Wong SP. Forming inferences about some intraclass correlation co-
efﬁcients. Psychol Methods 1996; 1:30.
24. Peugh JL. A practical guide to multilevel modeling. J Educ Psychol 2010; 48:
85–112.
25. Nakagawa S, Schielzeth H. A general and simple method for obtaining
R2 from generalized linear mixed-effects models. Methods Ecol Evol 2013;
4:133–42.
26. Refaeilzadeh P, Tang L, Liu H. Cross-validation. In: Liu L, Özsu MT, eds. Encyclo-
pedia of database systems. New York, NY: Springer US, 2009:532–8.
27. Zhang Y, Koukounari A, Kabatereine N, et al. Parasitological impact of 2-year pre-
ventive chemotherapy on schistosomiasis and soil-transmitted helminthiasis in
Uganda. BMC Med 2007; 5:27.
28. Fleming FM, Fenwick A, Tukahebwa EM, et al. Process evaluation of schistoso-
miasis control in Uganda, 2003 to 2006: perceptions, attitudes and constraints
of a national programme. Parasitology 2009; 136:1759–69.
29. Chami G, Molyneux D, Kontoleon A, Dunne D. Exploring network theory for
mass drug administration. Trends Parasitol 2013; 29:370–9.
30. Worrell C, Mathieu E. Drug coverage surveys for neglected tropical diseases: 10
years of ﬁeld experience. Am J Trop Med Hyg 2012; 87:216–22.
31. Kabatereine N, Brooker S, Tukahebwa E, Kazibwe F, Onapa A. Epidemiology and
geography of Schistosoma mansoni in Uganda: implications for planning control.
Trop Med Int Health 2004; 9:372–80.
32. Kabatereine N, Tukahebwa E, Kazibwe F, et al. Short communication: soil-trans-
mitted helminthiasis in Uganda: epidemiology and cost of control. Trop Med Int
Health 2005; 10:1187–9.
Mass Drug Administration Nonrecipients • CID 2016:62 (15 January) • 207
